Biotech’s China Problem[STAT Summit 2026 Review #07]

Report 07. Biotech’s China Problem

Part I. English Version

1. Event / Date & Time

Event: Biotech’s China Problem

Conference: STAT Summit 2026

Date & Time: October 14, 2026 | 11:35 AM EDT

2. Participants

Speakers

- Francisco Gimenez — Partner, 8VC

Moderator

- Damian Garde — Reporter at Large, STAT

3. Summary

Venture Model: A shift toward licensing Chinese assets could weaken U.S. venture firms’ capacity to create biotechnology companies and train new investors.

Domestic Infrastructure: The speaker advocated improving U.S. clinical-development infrastructure rather than relying primarily on investment relocation or restrictions.

Future Competition: AI-enabled entrants, Chinese commercialization ambitions, and global capital flows were presented as structural changes facing biotech and pharma.

4. Main Discussion

From Inventing Assets to Importing Them

Francisco Gimenez argued that traditional biotechnology venture investing risks losing a core capability as more funds license Chinese-developed molecules rather than build companies around domestic inventions. He acknowledged that lower development costs and attractive returns make these transactions rational for investors with obligations to limited partners. His concern was not the existence of cross-border deals but the cumulative effect on the U.S. company-creation ecosystem.

He distinguished the work of an investor who acquires an advanced asset from that of an investor who co-creates a company, builds a development plan and learns to manage early-stage scientific uncertainty. If younger general partners are trained mainly in importing candidates, he warned, the next generation may have fewer opportunities to learn how to establish companies from new U.S.-based discoveries.

Gimenez also pointed to weaknesses in venture-fund succession. In his assessment, many funds raised around 2020–2021 had struggled to advance from first to second funds, while successor teams and China-focused investment platforms were developing elsewhere. These were his observations of market dynamics, not a census of all biotechnology venture firms.

Clinical Trial Infrastructure and the Policy Response

Gimenez maintained that relocating research capital does not solve the underlying reasons U.S. clinical development has become expensive or slow. He cited difficulties conducting investigator-initiated studies, obtaining first-in-human data and navigating FDA-related processes. He urged experienced biotechnology practitioners to participate in reforming the systems they use, rather than treating relocation as the only available response.

Using a “voice versus exit” analogy, he said traditional funds have often chosen exit rather than advocacy. In his view, policymakers are willing to make changes but may adopt blunt restrictive measures when the sector fails to offer informed alternatives. He described testimony to Congress in March and discussions related to ARPA-H and efforts described as Operation Trial Blazer, which were presented as examples of attempts to accelerate clinical trials.

He did not endorse indiscriminate restrictions on imported molecules, instead urging targeted reform that responds to real bottlenecks. His central policy question was how to improve the speed, cost and reliability of U.S. clinical development so that local scientific inventions remain commercially viable.

The Emerging Roles of Technology Capital and AI

The speaker contrasted traditional biotech venture capital with technology venture firms entering drug discovery. He characterized technology VC as substantially larger—roughly ten times the scale of biotech VC in his formulation—and cited heavily financed AI-biotechnology ventures as evidence that investors are experimenting with different company-building models. Their ambition, he suggested, is sometimes to create lasting pharmaceutical enterprises rather than acquisition targets.

He discussed the possibility that AI and automation could lower the cost of taking an idea toward first-in-human development. One illustrative ambition was to reduce the amount of capital needed for an early company to below about $20 million, allowing a wider variety of founders and generalist investors to attempt drug development. These figures represented hypothetical business goals, not a demonstrated cost benchmark.

Gimenez questioned the division between low-risk incremental programs and revolutionary science. Capabilities developed through iterative chemistry, including outsourced antibody–drug conjugate work, can generate more sophisticated platforms. He therefore argued that an ecosystem that produces practical compounds also creates the skills and infrastructure needed for harder scientific bets.

Potential Implications for Large Pharmaceutical Companies

Asked about the future of large pharmaceutical companies, Gimenez suggested that distribution and commercialization in the U.S. remain important advantages for incumbent firms. However, he questioned the assumption that Chinese developers will remain content to license molecules while leaving downstream commercial revenue to established multinational companies.

He pointed to Chinese biotechnology firms’ expanding ambitions and suggested that future international competitors may increasingly pursue their own commercialization capabilities. In that scenario, Western companies could encounter pressure not only in sourcing research assets but also in the markets where approved drugs are sold. This was a forward-looking competitive assessment, not a confirmed outcome.

The session thus presented a dual challenge: preserving domestic invention and company-formation capacity while adapting to a more international drug-development ecosystem. Gimenez’s proposed response centered on stronger clinical infrastructure, deeper industry participation in policy design, and continued experimentation with venture-building models.

5. Insights

Innovation Ecosystem Resilience: A competitive biotech sector needs domestic capability to discover and build medicines, not only the ability to license advanced assets from abroad.

Implications for South Korea: Korea could balance cross-border licensing with clinical-trial infrastructure, founder training, and domestic venture-company formation.

Global Industry Transition: The expansion of Chinese R&D and AI-backed investment may change both upstream discovery and downstream commercialization, calling for flexible partnerships and policy engagement.

Report 07. Biotech’s China Problem_eng.pdf

Download PDF • 38KB